Notification of transactions by Primary Insiders (grant options)(20688350.1)
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-12-19 15:37:40
In connection with the appointment of Jonathan Allis to the board of directors
of EXACT Therapeutics AS ("EXACT-Tx" or the "Company"), Jonathan Allis has been
granted 63,263 options in the Company which will vest on a quarterly basis.
Please see the attached notification form for further information.
This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com
About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents across a multitude of indications including
within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com